Developing an accurate genetic model for rhabdomyosarcoma therapy testing
Rhabdomyosarcoma (RMS) is the third most common solid tumor in children and is often associated with high morbidity and mortality. The heterogenous nature of RMS along with the lack of genetically accurate mouse models has precluded this cancer from many of the therapy testing strategies currently being used for other malignancies. We hope to develop a mouse model that will accurately recapitulate the human disease including genetic heterogeneity and metastatic potential. These mice will allow testing for further classification of tumors that will aid in treatment decisions and be used to test novel therapies in pre-clinical trials for RMS treatment.